SCHEMBL16093483

SCHEMBL16093483

O=C(/C=C(O)/C=C/c1ccc(O)c(O)c1)/C=C/c1ccc(O)c(O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.68
KDM4E B2RXH2 2/20 0.68
HSD17B10 Q99714 2/20 0.68
GAA P10253 2/20 0.68
MAPT P10636 2/20 0.68
TTR P02766 2/20 0.68
APP P05067 2/20 0.68
MMP1 P03956 2/20 0.68
MMP2 P08253 2/20 0.68
MMP9 P14780 2/20 0.68
MEN1 O00255 1/20 0.68
HDAC3 O15379 1/20 0.68
CA12 O43570 1/20 0.68
AKR1B10 O60218 1/20 0.68
ALDH1A1 P00352 1/20 0.68
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
LMNA P02545 1/20 0.68
GLA P06280 1/20 0.68
POLB P06746 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13953735 0.89 BACE1 (0.57) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL22902413 0.87 GSK3B (0.81) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL5598948 0.87 KDM4E (0.74) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL2221673 0.87 KDM4E (0.74) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL23260803 0.86 HSD17B10 (0.64) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL20978310 0.86 IAPP (0.67) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL30851321 0.86 IAPP (0.67) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL611054 0.85 BACE1 (0.60) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL611055 0.85 BACE1 (0.60) BACE1KDM4EHSD17B10GAAMAPT
SCHEMBL26555577 0.85 FOS (0.63) BACE1KDM4EHSD17B10GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017218219-A1 NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT CHINA MEDICAL UNIVERSITY (TW) 2017-12-21 WO disclosed
US-20160039734-A1 THERAPEUTIC CURCUMIN DERIVATIVES STC UNM (US) 2016-02-11 US disclosed
US-20150232642-A1 POLYMERIC NANOPARTICLES COMPRISING TURMERIC XEROX CORPORATION (US) 2015-08-20 US disclosed
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES STC.UNM 2015-01-08 US disclosed
US-8841326-B2 Therapeutic curcumin derivatives STC.UNM (US) 2014-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039734-A1 THERAPEUTIC CURCUMIN DERIVATIVES FABP2, GLS2, FABP1 BACE1 750/4885KDM4E 3658/4885HSD17B10 768/4885
US-20150011494-A1 THERAPEUTIC CURCUMIN DERIVATIVES FABP2, GLS2, FABP1 BACE1 750/4885KDM4E 3658/4885HSD17B10 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.